-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Roy Zwahlen
Roy is a Manager of Intellectual Property and Technology Transfer policy at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his two kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.
Latest Posts
Debunking the Myth: Your Genes are Patented
MYTH: YOUR GENES ARE PATENTED. FACTS: IT IS NOT POSSIBLE TO PATENT YOUR GENES The term “gene patent” is a misnomer, because genes as they exist in the body cannot be patented. Because a naturally-occurring gene – even a newly-discovered one – cannot be patented, patents don’t provide ownership rights over our genes, and nobody can infringe a patent by having a certain gene, or by passing it on to their children. If genes aren’t Read More >
USPTO Biotechnology/Chemical/Pharmaceutical Customer Partnership Meeting
Biotechnology/Chemical/Pharmaceutical Customer Partnership Wednesday, June 8, 2011 Meeting Madison Auditorium Starting Time of 10:00 AM United States Patent and Trademark Office Alexandria, Virginia 600 Dulany Street, Alexandria, VA, Accessing the event: Double click on the link below (or copy it into your internet browser) https://uspto.connectsolutions.com/r80345544/ Click here for detailed login instructions in MS Word. Driving & Metro Directions /Hotels (Word) Campus Map (html) Campus Map (Power Point) Morning Session 10:00 – 10:30 AM. Greetings, TC Update Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BCP, biotechnology, Biotechnology Chemical Pharmaceutical Customer Partnership Meeting, Clearing the Oldest Patent Applications (COPA), Expedited Examinations, Green Tech, Microsoft v. i4i Ltd., Patent Prosecution Highway, Plant Utility Patents, Track 1, USPTO
Tags: BCP, biotechnology, Biotechnology Chemical Pharmaceutical Customer Partnership Meeting, Clearing the Oldest Patent Applications (COPA), Expedited Examinations, Green Tech, Microsoft v. i4i Ltd., Patent Prosecution Highway, Plant Utility Patents, Track 1, USPTO
BIO’s “What Every State Should Know About Bayh-Dole” Webinar
The Biotechnology Industry Organization (BIO) recently hosted a webinar entitled: “What Every State Should Know About Bayh-Dole: Leveraging University Research to Create Jobs and Spur Economic Development Benefits.” The Bayh-Dole Act, enacted in 1980, placed patent ownership of federally funded research at universities in the hands of the university and enabled universities to out-license technologies for commercialization. As a result of the Act, more than 7200 companies were created (including nearly 600 last year despite Read More >
Huffington Post: Data Exclusivity: Getting the Balance Right
Huffington Post: Data Exclusivity: Getting the Balance Right A great article on the downsides of cutting or removing data exclusivity provisions for biologics. The article points out that data protection is needed to enhance safety and create incentives to research and produce new innovative drugs that cost billions of dollars. However, the author argues that the period must be limited somehow (not 50 years) to ensure generics can entire the market and lower costs. Finally, the author states that lowering the data exclusivity Read More >
